Target intelligence / Profile preview

Heat shock protein 16.3 (Hsp16.3) (Hsp16.3)

Target
Hsp16.3
Molecular classification
Small heat shock protein, Chaperone, Alpha-crystallin family
01

Overview

Heat shock protein 16.3 (Hsp16.3), also known as HspX or Acr, is a small heat shock protein (sHSP) produced by Mycobacterium tuberculosis (Mtb) [1, 3]. It belongs to the alpha-crystallin family and functions as a molecular chaperone that prevents the aggregation of denatured proteins under stress conditions [3, 11]. Hsp16.3 is predominantly expressed during the stationary phase and is essential for the long-term survival and dormancy of the pathogen within the host, particularly during latent tuberculosis infection (LTBI) [1, 5]. It contributes to cell wall thickening and helps the bacteria evade host immune responses by inhibiting macrophage autophagy and inducing M2 polarization [1, 8, 32]. Due to its high expression in latent stages and strong immunogenicity, Hsp16.3 is a major target for the development of diagnostic biomarkers, vaccines, and novel therapeutic interventions aimed at eradicating dormant bacilli [4, 6, 21]. Experimental approaches include the use of specific antibodies and peptide inhibitors to disrupt its chaperone function or enhance host clearance of the bacteria [2, 20, 24]. Targeting Hsp16.3 may provide a strategy to shorten tuberculosis treatment regimens and prevent disease reactivation [21, 23].

Other names
HspXAcrAcr116 kDa antigenAlpha-crystallin-related protein 1Rv2031c
02

Mechanism of action

Inhibition of chaperone activity to disrupt bacterial dormancy and survival; modulation of host immune response to enhance bacterial clearance; reversal of autophagy inhibition in macrophages.

03

Biological functions

Molecular chaperoneProtein folding and stabilizationSurvival during dormancy and latencyCell wall thickeningInhibition of macrophage autophagyInduction of macrophage M2 polarization
04

Disease associations

TuberculosisLatent tuberculosis infectionSarcoidosis
05

Safety considerations

High immunogenicity of the proteinTherapeutic challenge of targeting dormant bacilli within granulomasPotential for inflammatory response or cross-reactivity
06

Interacting drugs

Streptomycin

5 more in the full profile.

07

Biomarkers

Hsp16.3 proteinAnti-Hsp16.3 antibodiesExosomal Hsp16.3Hsp16.3-specific T cells

Beyond the preview

Go deeper on Heat shock protein 16.3 (Hsp16.3) (Hsp16.3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heat shock protein 16.3 (Hsp16.3) (Hsp16.3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call